The Hydration to Optimize Metabolism (H2O Metabolism) Pilot Study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Region Skane
- Enrollment
- 34
- Locations
- 1
- Primary Endpoint
- Fasting plasma copeptin concentration (pmol/L)
Study Overview
Brief Summary
This study evaluates increased hydration (1.5 L of water daily during 6 weeks) on top of habitual water intake in the lowering of the vasopressin marker copeptin and in the lowering of plasma glucose concentration in adults with signs of low water intake at recruitment (elevated levels of copeptin, high urine osmolality, low urine volume).
Detailed Description
High plasma concentration of vasopressin (i.e. antidiuretic hormone) is a novel and independent risk factor for type 2 diabetes, the metabolic syndrome, cardiovascular disease and premature death. The main physiological role of vasopressin is to maintain constant plasma osmolality. Previous studies in rats and a Mendelian randomization study in humans suggest causality between elevated vasopressin concentration and elevated plasma glucose concentration. As vasopressin can be suppressed by increasing water intake, the investigators hypothesize that water supplementation in individuals with high vasopressin can lower plasma glucose and prevent diabetes.
The aim of this pilot study is to test if six weeks of water supplementation of 1.5 Liters of extra water per day in low-drinkers with high copeptin can significantly alter hydration markers in general and reduce plasma copeptin in particular. Furthermore, the investigators also aim at investigating whether this 6-week water intervention can significantly reduce fasting plasma glucose concentration.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 20 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Provision of informed consent
- •Age 20-75 years
- •High plasma concentration of copeptin of >6.1 pmol/L in women and > 10.7 pmol/L in men
- •24-hour urine osmolality > 600 milliosmol (mosm) /kg water.
Exclusion Criteria
- •24-hour urine volume >1.5 L
- •Pregnancy or breastfeeding
- •Plasma sodium <135 mmol/L
- •Use of diuretics, lithium or SSRI drugs
- •Chronic kidney disease (estimated glomerular filtration rate < 30mL/min)
- •Heart failure
- •Inflammatory bowel disease
- •Type 1 diabetes or type 2 diabetes treated with insulin
- •Vulnerable subjects (subjects with legal guardian, with loss of personal liberty)
Arms & Interventions
Water intervention
The participants increase their habitual daily water intake with 1.5 Liters of tap water per day during 6 weeks.
Intervention: Water (Dietary Supplement)
Outcomes
Primary Outcomes
Fasting plasma copeptin concentration (pmol/L)
Time Frame: 6 weeks
Change of fasting plasma copeptin between baseline and after 6 weeks of increased water intake.
Secondary Outcomes
- 24 hour urine volume (L/24h)(6 weeks)
- 24 hour urine osmolality (mosm/kg H2O)(6 weeks)
- Drinking water (L/day)(6 weeks)
- Total water (L/day)(6 weeks)
- Fasting plasma glucose concentration (mmol/L)(6 weeks)
Investigators
Olle Melander
Professor
Region Skane